Bioavailability of BMS-986205 in Healthy Participants

Phase 1, randomised, open-label trial of linrodostat in solid tumor (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration (Cmax) of single 100 mg dose of BMS-986205 administered orally as crushed tablet on soft food compared to intact tablet administered orally up to 22 days, Maximum observed plasma concentration (Cmax) of single 100 mg dose of BMS-986205 administered via nasogastric (NG) tube as crushed tablet suspension compared to intact tablet administered orally up to 22 days and 2 more. Started Nov 2017; status: completed.